Advaxis to Present at the 2017 Barclays Global Healthcare Conference
March 13 2017 - 8:00AM
Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company
developing cancer immunotherapies, today announced that Sara
Bonstein, Chief Financial Officer of Advaxis, will present a
corporate overview at the 2017 Barclays Global Healthcare
Conference being held in Miami on March 14-16.
Event: 2017 Barclays Global Healthcare
Conference Presentation Date: March 14, 2017
Presentation Time: 8:30 a.m. ET
Location: Loews Miami Beach Hotel, Miami
Beach, FL
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a
biotechnology company developing multiple cancer immunotherapies
based on its proprietary Lm Technology™.
The Lm Technology, using bioengineered live
attenuated Listeria monocytogenes (Lm) bacteria, is the
only known cancer immunotherapy agent shown in preclinical studies
to both generate cancer fighting T cells directed against cancer
antigens and neutralize Tregs and myeloid-derived suppressor cells
(MDSCs) that protect the tumor microenvironment from immunologic
attack and contribute to tumor growth. Advaxis'
lead Lm Technology immunotherapy, axalimogene filolisbac,
targets HPV-associated cancers and is in clinical trials for three
potential indications: Phase 3 in invasive cervical cancer, Phase 2
in head and neck cancer, and Phase 2 in anal cancer. The FDA has
granted axalimogene filolisbac orphan drug designation for each of
these three clinical settings, as well as Fast Track designation
for adjuvant therapy for high risk locally advanced cervical cancer
(HRLACC) patients and a SPA for the Phase 3 AIM2CERV trial in
HRLACC patients. Axalimogene filolisbac has also been classified as
an advanced therapy medicinal product for the treatment of cervical
cancer by the EMA’s CAT. Advaxis has two additional immunotherapy
products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2
expressing solid tumors, in human clinical development. In
addition, Advaxis and Amgen are developing ADXS-NEO, a preclinical
investigational cancer immunotherapy treatment designed to activate
a patient's immune system to respond against the unique mutations,
or neoepitopes, contained in and identified from each individual
patient's tumor, with plans to enter the clinic in 2017.
To learn more about Advaxis, visit
www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and
YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking
statements, including, but not limited to, statements regarding
Advaxis’ ability to develop the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapy, axalimogene filolisbac. These
forward-looking statements are subject to a number of risks
including the risk factors set forth from time to time in Advaxis’
SEC filings including, but not limited to, its report on Form 10-K
for the fiscal year ended October 31, 2016, which is available at
http://www.sec.gov.
Any forward-looking statements set forth in this
presentation speak only as of the date of this presentation. We do
not intend to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof
other than as required by law.
You are cautioned not to place undue reliance on
any forward-looking statements.
CONTACTS:
Company:
Advaxis, Inc. Ranya Dajani, Vice President, Business Development
dajani@advaxis.com 609.250.7559
Media Contact:
JPA Health Communications David Connolly dconnolly@jpa.com
617.945.9316
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024